Treatment of neuroblastoma using the fused imaging guided radiotherapy (FIGURA) system

Eyal Fenig*, Moshe Mishaeli, Rinat Yerushalmi, Zvi Bar Sever, Shifra Ash, Liora Kornreich, Itzak Yaniv, Adam Steinmetz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


PURPOSE: The purpose of this study was to describe our department's experience with the fused imaging-guided radiotherapy (FIGURA) system for planning radiation treatment of high-risk neuroblastoma. PATIENTS AND METHODS: Between 1999 and 2002, 11 patients received radiation therapy as consolidation after chemotherapy in 9 and for palliation in 2. Diagnostic metaiodobenzylguanidine (MIBG) imaging was used, which is specific for neuroblastoma, to identify the residual tumor, followed by computed tomography scanning in the radiation treatment position. The FIGURA software fused the images obtained by the 2 modalities and transferred the result to a 3-dimensional radiation treatment planning system. Radiation was delivered at a total dose of 25.2 Gy according to the FIGURA. RESULTS: Five patients achieved complete remission and 2 partial remission; 3 were stabilized. One child with a highly rapid progressive course died of the disease. CONCLUSION: FIGURA is a new, feasible technique for defining target volumes. By using standard hospital equipment, it is possible to treat residual disease identified by sensitive metaiodobenzylguanidine imaging and localized with the anatomic computed tomography scan. Treating a more accurate target volume spares normal tissue and organs and minimizes side effects.

Original languageEnglish
Pages (from-to)256-258
Number of pages3
JournalClinical Nuclear Medicine
Issue number5
StatePublished - May 2006


  • Biologic target volume
  • Fused imaging
  • MIBG
  • Neuroblastoma
  • Radiotherapy


Dive into the research topics of 'Treatment of neuroblastoma using the fused imaging guided radiotherapy (FIGURA) system'. Together they form a unique fingerprint.

Cite this